Clinical Trial Update: Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria [Phase 2, Phase 3]

View source ↗

Summary

An ongoing Phase 2/3 clinical trial evaluating the efficacy and safety of ICP-332 in people with chronic spontaneous urticaria; recruitment is currently active.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• ICP-332

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Chronic Spontaneous Urticaria (CSU) | Phase 2, Phase 3 | Status: RECRUITING